Release Date: 2022-03-15

Molecular Biological Basis of Cognitive Disorders in Cancer

Ozgur Tanriverdi (Author)

Release Date: 2022-03-15

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inA Handbook on Chemobrain with Molecular and Clinical Background
First Page39
Last Page45
DOIhttps://doi.org/10.69860/nobel.9786053358985.6
ISBN978-605-335-898-5 (PDF)
LanguageENG
Page Count7
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Ozgur Tanriverdi (Author)
Associate Professor, Muğla Sıtkı Koçman University
https://orcid.org/0000-0002-0598-7284

  • Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standarddose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485-93.

  • Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncol. 2003; 12: 612-9.

  • Ahles TA, Saykin AJ. Candidate mechanism for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007; 7: 192-201.

  • Ai S, Shen L, Guo J, et al. DNA methylation as a biomarker for neuropsychiatric diseases. Int J Neurosci. 2012; 122: 165-76.

  • Anderson-Hanley C, Sherman ML, Riggs R, et al. Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003; 9: 967-82.

  • Argyriou AA, Assimakopoulos K, Iconomou G, et al. Either called “chemobrain” or “chemofog”, the long-term chemotherapy-induced cognitive decline in cancer survival is real. J Pain Symptom Manage. 2011; 41: 126-39.

  • Banach M, Juranek JK. Chemobrain- A troubling side effect of chemotherapy. J Depress Anxiety. 2017; S11: 002.

  • Bender C, Merriman J. Cancer and treatment-treated cognitive changes: What can we do now? What lies ahead? Oncology 2014; 28: 201379.

  • Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004; 26: 955-69.

  • Chen Y, Jungsuwadee P, Vore M, et al. Collateral damage in cancer chemotherapy:Oxidative stress in non-targeted tissues. Mol Interv. 2007; 7: 147-56.

  • Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biological mechanism? A cytokine- immunologic model of cancer symptoms. Cancer 2003; 97: 2919- 25.

  • Coldecott KW. DNA single-strand breaks and neurodegeneration. DNA Repair (Amst) 2004; 3: 875-82.

  • Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of hormonal therapy in early stage breast cancer patients: A prospective study. Psychooncol. 2009; 18: 811-21.

  • Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006; 5: 22.

  • Ernst T, Chang L, Cooray D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002; 94: 592-7.

  • Ferguson RJ, Ahles TA. Chemotherapy associated cognitive impairment in patients with cancer and cancer survivors. Curr Neurol Neurosci Rep. 2003; 3: 215-22.

  • Jansen J, Miaskowski C, Dodd M, et al. Potential mechanisms for chemotherapy-induced impairments in cognitive function. Oncol Nurs Forum. 2005; 32:1151-63.

  • Lee S, Lee HJ, Kang H, et al. Trastuzumab induced chemobrain, atorvastatin rescued chemobrain with enhanced anticancer effect and without hair-loss side effect. J Clin Med. 2019; 8: 234.

  • Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol. 1999; 461: 75-8.

  • Mifsud KR, Gutierrez-Mecinas M, Trollope AF, et al. Epigenetic mechanisms in stress and adaptation. Brain Behav Immun. 2011; 25: 1305-15.

  • Neuwelt EA, Baver B, Fahlke C, et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci. 2011; 12: 169-82.

  • Salmiren EK, Portin RI, Koskiren A, et al. Association between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res. 2004;10: 7575-82.

  • Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological, and neuroimaging perspective. Semin Clin Neuropsychiatry. 2003; 8: 201- 16.

  • Tanggong J, Cole MP, Sultana R, et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: Insights into the mechanism of chemobrain. J Neurochem. 2007; 100: 191-201.

  • Walczak P, Janowski M. Chemobrain is a product of growing success in chemotherapy-focus on glia as both a victim and a cure. Neuropsychiatry 2019; 9:2207-16.

  • Wang XM, Walitt B, Saligan L, et al. Chemobrain: A critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine 2015; 72: 86-96.

  • Weiss B. Chemobrain: A translational challenges for neurotoxicology. Neurotoxicol.col.2008; 29: 891-8.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!